A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

• Status: Completed
• Trial end date: 2020-08-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: AbCellera Biologics Inc.

Criteria

Inclusion Criteria:

• Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to (≤)72 hours prior to randomization

• Are men or non-pregnant women

• Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study

• Agree to the collection of nasopharyngeal swabs and venous blood

Exclusion Criteria:

• Require mechanical ventilation or anticipated impending need for mechanical ventilation

• Received convalescent COVID-19 plasma treatment prior to enrollment

• Were resident in a nursing home or long-term care facility immediately prior to current hospitalization

• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product

• Have an oxygen saturation (SpO2) less than (<)88 percent (%) while breathing room air at rest at randomization.